Gold prices steady ahead of Fed decision; weekly weakness noted
LONDON - PureTech Health plc (Nasdaq:PRTC, LSE: PRTC) reported Friday that Robert Lyne, Chief Portfolio Officer, received vested ordinary shares on July 1, 2025, as part of restricted share units (RSUs) granted on March 4, 2024, under the company’s Performance Share Plan.
According to the company statement, 25% of the shares vested on February 1, 2025, with Lyne receiving the vested ordinary shares after tax deductions on July 1. The market price used to calculate the payment was 125.93 pence per share, based on the average closing price over three trading days prior to issuance, with an exchange rate of £1: $1.37.
PureTech also disclosed that Lyne sold 33,561 ordinary shares at 125.05 pence per share on July 1, and subsequently purchased the same number of shares at 125.78 pence per share into his Self-Invested Personal Pension (SIPP) on the same day.
Following the share issuance to Lyne, PureTech’s total issued ordinary share capital stands at 257,927,489 shares, with 17,639,479 shares held in treasury by the company.
The notification was made in accordance with Article 19 of the EU Market Abuse Regulation, as stated in the press release.
PureTech Health is a clinical-stage biotherapeutics company focused on developing new classes of medicine for patients with various diseases.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.